Pulmonx Q4 Earnings Call Highlights [Yahoo! Finance]
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: Yahoo! Finance
challenges,” including disruptive territory changes and incentive design that contributed to turnover of about half of the sales organization ; the CEO has taken direct control of U.S. sales, priorities are being streamlined, and management expects U.S. growth to resume in the back half of 2026 as territories ramp (typically 6–9 months). AeriSeal and the pivotal CONVERT II trial are being prioritized as the nearest-term market-expansion effort to treat severe COPD patients with collateral ventilation who aren't candidates for Zephyr valves, with enrollment expected to finish in 2027 and the company estimating a potential ~20% expansion of its global TAM. Pulmonx completed a cost restructure that cut ongoing operating expenses by 10%, secured a $60 million credit facility (extending debt to 2031) and expects to reduce annual cash burn from $32M in 2025 to $23M in 2026; 2026 revenue guidance is $ 90–92 million with management forecasting improvement in the second half of the year.
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- Pulmonx (LUNG) had its price target lowered by Canaccord Genuity Group Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Pulmonx (LUNG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Sales Force ... [Yahoo! Finance]Yahoo! Finance
- Pulmonx (LUNG) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Pulmonx Corporation (LUNG) Q4 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
LUNG
Earnings
- 3/4/26 - Beat
LUNG
Analyst Actions
- 3/5/26 - Canaccord Genuity
LUNG
Sec Filings
- 3/10/26 - Form S-8
- 3/10/26 - Form 10-K
- 3/9/26 - Form SCHEDULE
- LUNG's page on the SEC website